|
leukemia
|
0.010 |
Biomarker
|
disease |
LHGDN |
The membrane-proximal immunoreceptor tyrosine-based inhibitory motif is critical for the inhibitory signaling mediated by Siglecs-7 and -9, CD33-related Siglecs expressed on human monocytes and NK cells.
|
15557178 |
2004 |
|
Neoplasms
|
0.050 |
Biomarker
|
group |
BEFREE |
Here we used affinity chromatography of tumor cell extracts to identify LGALS3BP as a novel sialic acid-dependent ligand for human Siglec-9 and for other immunomodulatory Siglecs, such as Siglec-5 and Siglec-10.
|
25320078 |
2014 |
|
Neoplasms
|
0.050 |
Biomarker
|
group |
BEFREE |
Tumor-associated MUC1 binds to Siglec-9, which is expected to mediate tumor cell growth and negative immunomodulation.
|
24924635 |
2014 |
|
Neoplasms
|
0.050 |
Biomarker
|
group |
BEFREE |
Supporting this hypothesis, Siglec-9-expressing myelomonocytic cells found in human tumor samples were accompanied by a strong up-regulation of Siglec-9 ligands.
|
25225409 |
2014 |
|
Carcinoma
|
0.010 |
Biomarker
|
group |
BEFREE |
In keeping with this, a human polymorphism that reduced Siglec-9 binding to carcinomas was associated with improved early survival in non-small-cell lung cancer patients, which suggests that Siglec-9 might be therapeutically targeted within the right time frame and stage of disease.
|
25225409 |
2014 |
|
Septicemia
|
0.010 |
Biomarker
|
disease |
BEFREE |
Our findings have implications for the inhibitory role of siglec-9 on human neutrophils in sepsis and acute lung injury.
|
24895121 |
2014 |
|
Sepsis
|
0.010 |
Biomarker
|
disease |
BEFREE |
Our findings have implications for the inhibitory role of siglec-9 on human neutrophils in sepsis and acute lung injury.
|
24895121 |
2014 |
|
Neoplasms
|
0.050 |
Biomarker
|
group |
BEFREE |
Here we found that this cancer-specific MUC1 glycoform, through engagement of Siglec-9, 'educated' myeloid cells to release factors associated with determination of the tumor microenvironment and disease progression.
|
27595232 |
2016 |
|
Chronic Obstructive Airway Disease
|
0.020 |
GeneticVariation
|
disease |
BEFREE |
Influence of SIGLEC9 polymorphisms on COPD phenotypes including exacerbation frequency.
|
27878892 |
2017 |
|
Chronic Obstructive Airway Disease
|
0.020 |
Biomarker
|
disease |
BEFREE |
In conclusion, Siglec-9 was complementarily increased to induce a negative feedback loop to limit neutrophil activation in COPD, sSiglce-9 enhanced neutrophil ROS and chemotaxis toward IL-8 likely via competitively inhibiting ligands binding to Siglec-9.
|
28860481 |
2017 |
|
Arthritis
|
0.010 |
Biomarker
|
disease |
BEFREE |
Furthermore, administration of recombinant human Siglec-9 Fc chimera protein significantly attenuated collagen-induced arthritis development in vivo and in vitro by reciprocal regulation of the differentiation of Th17 and Treg cells.
|
28273363 |
2017 |
|
Rheumatoid Arthritis
|
0.010 |
Biomarker
|
disease |
BEFREE |
In conclusion, Siglec-9 may serve as a potential diagnostic and therapeutic target for RA.
|
28273363 |
2017 |
|
Pulmonary Emphysema
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
The G allele of rs2075803 and rs2075803 G/rs2258983 A(GA) haplotype in SIGLEC9 was associated with higher frequency of exacerbations and the extent of emphysema in COPD.
|
27878892 |
2017 |
|
Liver Failure, Acute
|
0.010 |
Biomarker
|
disease |
BEFREE |
Secreted Ectodomain of SIGLEC-9 and MCP-1 Synergistically Improve Acute Liver Failure in Rats by Altering Macrophage Polarity.
|
28272428 |
2017 |
|
COPD exacerbation
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
We examined whether SIGLEC9 polymorphisms affect the frequency of COPD exacerbation in 135 subjects within our study population, and also analysed the correlation between the genotypes and the severity of airflow obstruction and emphysema in 362 Japanese smokers including 244 COPD patients.
|
27878892 |
2017 |
|
Tumor Immunity
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
Siglec 9 on neutrophils and Siglec 7 on NK cells are prominent examples of inhibitory Siglecs that can potentially dampen anti-tumor immunity.
|
28258691 |
2017 |
|
Body mass index
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Protein-altering variants associated with body mass index implicate pathways that control energy intake and expenditure in obesity.
|
29273807 |
2018 |
|
Blood Protein Measurement
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Genomic atlas of the human plasma proteome.
|
29875488 |
2018 |
|
Asthma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Targeting Neutrophils in Severe Asthma via Siglec-9.
|
29306942 |
2018 |
|
Non-Small Cell Lung Carcinoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
T cell expression of Siglec-9 in NSCLC patients correlated with reduced survival, and Siglec-9 polymorphisms showed association with the risk of developing lung and colorectal cancer.
|
30130255 |
2018 |
|
Chikungunya Fever
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Expression of Siglec-9 on monocytes; which can modulate oxidative stress is studied along with intracellular reactive oxygen species (ROS), cellular lipid and protein damage markers in chikungunya patients with/without persisting polyarthralgia along with healthy controls.
|
29898618 |
2018 |
|
Colorectal Carcinoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
T cell expression of Siglec-9 in NSCLC patients correlated with reduced survival, and Siglec-9 polymorphisms showed association with the risk of developing lung and colorectal cancer.
|
30130255 |
2018 |
|
Guillain-Barre Syndrome
|
0.010 |
Biomarker
|
disease |
BEFREE |
Transgenic mice expressing the soluble form of Siglec-9 showed significant resistance against GBS infection and remarkable suppression of MUC1 expressing tumor proliferation.
|
29342882 |
2018 |
|
Lung diseases
|
0.010 |
Biomarker
|
group |
BEFREE |
Given that neutrophils are probably a major culprit in the generation and perpetuation of inflammation, targeting Siglec-9 could be beneficial for the treatment of severe asthma, chronic obstructive pulmonary disease, and related pulmonary disorders characteristic of neutrophilia.
|
29306942 |
2018 |
|
Complete atrioventricular block
|
0.010 |
Biomarker
|
disease |
BEFREE |
Neutralization of Siglec-9 restored cytokine synthesis and degranulation of NK cells from CHB patients.
|
29899741 |
2018 |